Evidence map›Paper›PMID 26011050›Full record

Trial reportBritish journal of clinical pharmacology2015

Moxifloxacin-induced QTc interval prolongations in healthy male Japanese and Caucasian volunteers: a direct comparison in a thorough QT study.

Joel Morganroth, Yaning Wang, Michael Thorn, Yuji Kumagai, Stuart Harris, Norman Stockbridge, Robert Kleiman, Rashmi Shah

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in British journal of clinical pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 4 countries.

Joel MorganrothEResearch Technology Inc., Philadelphia.
Yaning WangDivision of Pharmacometrics, Food and Drug Administration, Silver Spring, Maryland.
Michael ThornStatistical Resources Inc., Chapel Hill, North Carolina, USA.
Yuji KumagaiClinical Research Centre, Kitasato University East Hospital, Sagamihara, Japan.
Stuart HarrisSeaView Research Inc., Miami, Florida.
Norman StockbridgeDivision of Cardiovascular and Renal Products, Food and Drug Administration, Silver Spring, Maryland, USA.
Robert KleimanEResearch Technology Inc., Philadelphia.
Rashmi ShahGerrards Cross, Buckinghamshire, UK.
ERT (Germany) · DEUnited States Food and Drug Administration · USChalfonts and Gerrards Cross Hospital · GBKitasato University Hospital · JPSeaView Research · USStatistical Research (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimWe investigated whether moxifloxacin-induced QTc prolongations in Japanese and Caucasian healthy male volunteers were significantly different.

methodsA two period, randomized, crossover, ICH-E14-compliant thorough QT (TQT) study compared placebo-corrected changes in QTc interval from baseline (ΔΔQTc F) and concentration-effect relationships following administration of placebo and 400 mg moxifloxacin to 40 healthy male volunteers from each ethnic population. The point estimates of ΔΔQTc F for each population, and the difference between the two, were calculated at a geometric mean Cmax of moxifloxacin using a linear mixed effects model. The concentration-effect slopes of the two populations were also compared. Equivalence was concluded if the two-sided 90% confidence interval of the difference in ΔΔQTc F was contained within -5 ms to +5 ms limits and the ratio of the slopes was between 0.5 and 2.

resultsThere were no statistically significant differences between the two populations studied, Japanese vs. Caucasians, respectively, for moxifloxacin Cmax (3.27 ± 0.6 vs. 2.98 ± 0.7 µg ml(-1) ), ΔΔQTc F (9.63 ± 1.15 vs. 11.46 ± 1.19 ms at Cmax of 3.07 µg ml(-1) ) and concentration-response slopes (2.58 ± 0.62 vs. 2.34 ± 0.64 ms per µg ml(-1) ). The difference in the two ΔΔQTc F of -1.8 (90% CI -4.6, 0.9) and the ratio of the two slopes (1.1; 90% CI 0.63, 1.82) were within pre-specified equivalence limits.

conclusionsMoxifloxacin-induced QTc prolongations did not differ significantly between the Japanese and Caucasian subjects. However, before our findings are more widely generalized, further studies in other populations and with other QT-prolonging drugs are needed to clarify whether inter-ethnic differences in QT sensitivity exist and whether ethnicity of the study population may affect the outcome of a TQT study.

Indexed as

Asian PeopleWhite PeopleAdministration, OralAdultAnti-Bacterial AgentsCross-Over StudiesDose-Response Relationship, DrugElectrocardiographyFluoroquinolonesHealthy VolunteersHeart RateHumansLong QT SyndromeMaleMoxifloxacinProspective StudiesAnti-Bacterial AgentsFluoroquinolonesMoxifloxacinCaucasiansethnicityJapanesemoxifloxacinQTc intervalthorough QT studies

Identifiers

PMID26011050
PMCPMC4574830
OpenAlexW1524573729

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.